3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
2
Thoracic
1
Sarcoma
1
Other solid neoplasm
1
NET
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Breast
1
Conditions
Carcinoma, Renal Cell
4
Carcinoma, Transitional Cell
3
Carcinoma, Non-Small-Cell Lung
3
Stomach Neoplasms
2
Neoplasm Metastasis
2
Colorectal Neoplasms
2
Carcinoma, Hepatocellular
2
Wilms Tumor
1
Uterine Cervical Neoplasms
1
Urothelial Cancer (Urinary Bladder, Ureters, or Renal Pelvis Cancer)
1
Turcot syndrome
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Thrombocytosis
1
Tertiary Lymphoid Structures
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Neuroblastoma
1
Neoplasms
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Interventions
Magnetic Resonance Spectroscopy
4
pembrolizumab
3
Trastuzumab
3
Sunitinib
3
Nivolumab
3
ulixertinib
2
tipifarnib
2
palbociclib
2
lenvatinib
2
belinostat
2
Specimen Handling
2
Sirolimus
2
Radiosurgery
2
Immunoglobulin G
2
Fluorodeoxyglucose F18
2
FAPI-46
2
Disulfides
2
vandetanib
1
tumor necrosis factor-alpha, CNGRC fusion protein, human
1
trastuzumab deruxtecan
1
trastuzumab biosimilar HLX02
1
trametinib
1
tislelizumab
1
temsirolimus
1
spartalizumab
1
sargramostim
1
sapanisertib
1
romidepsin
1
relatlimab
1
regorafenib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Thyroid Neoplasms
×
regorafenib
×
Genitourinary
×
Clear all
NCT03475953
2023-03-03
REGOMUNE
Institut Bergonié
Phase 1/2
Unknown
747 enrolled